Lifecore Biomedical Secures Two New CDMO Deals, Including Commercial Site Transfer, Boosting 2028 Revenue Outlook
summarizeSummary
Lifecore Biomedical has signed two new contract development and manufacturing organization (CDMO) agreements with an existing U.S. biopharmaceutical customer. One agreement involves a commercial site transfer for a product new to Lifecore, while the second expands manufacturing for an existing product to a new delivery system. This positive development follows the company's announcement on March 23 of another commercial site transfer agreement and helps to counter the negative sentiment from the March 16 news regarding an expected customer loss and reduced revenue guidance. These agreements, representing the fourth commercial site transfer win in five months, are expected to contribute to Lifecore's commercial revenue starting in 2028. For this small-cap company, these wins are material, demonstrating successful execution of its commercial strategy and providing a clear positive catalyst for future growth. Investors should monitor the progress of these technical transfers and any further announcements of new commercial partnerships.
At the time of this announcement, LFCR was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157M. The 52-week trading range was $3.87 to $8.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.